Keymed Biosciences Inc. Stock
Stocks
2162
KYG5252B1023
Biotechnology & Medical Research
OTC Markets Traded|
Delayed
Hong Kong S.E.
08:08:52 20/08/2026 +03
|
5-day change | 1st Jan Change | ||
| 81.30 HKD | +5.52% |
|
+2.65% | +52.01% |
| 08-19 | Keymed Biosciences Inc. Reports Earnings Results for the Half Year Ended June 30, 2026 | CI |
| 08-10 | Keymed Biosciences' Nasal Polyp Drug Trial Meets All Phase 2 Endpoints | MT |
| Market Cap | 19.49B 22.7B 2.89B 2.48B 2.32B 2.13B 4B 277B 4.07B 27.36B 10.71B 139B 10.87B 10.63B 459B | P/E 2026 * |
25.6x | P/E 2027 * | 1,341x |
|---|---|---|---|---|---|
| Enterprise Value | 18.24B 21.25B 2.71B 2.32B 2.17B 1.99B 3.74B 259B 3.81B 25.61B 10.03B 130B 10.18B 9.95B 430B | EV / Sales 2026 * |
8.06x | EV / Sales 2027 * | 8.52x |
| Free-Float |
74.84% | Yield 2026 * |
-
| Yield 2027 * | - |
| 1 day | +5.45% | ||
| 1 week | +2.65% | ||
| Current month | +11.15% | ||
| 1 month | -6.82% | ||
| 3 months | +32.44% | ||
| 6 months | +49.49% | ||
| Current year | +52.01% |
| 1 week | 75.15 |  | 83.05 |
| 1 month | 71.15 | | 88.8 |
| Current year | 44.66 | | 89.75 |
| 1 year | 44.66 | | 89.75 |
| 3 years | 26.6 | | 89.75 |
| 5 years | 16.9 | | 89.75 |
| 10 years | 16.9 | | 89.75 |
| Manager | Title | Age | Since |
|---|---|---|---|
Bo Chen
CEO | Chief Executive Officer | 52 | 23/04/2018 |
Changyu Wang
PRN | Corporate Officer/Principal | 61 | 03/03/2021 |
Pak Yu Tam
SEC | Corporate Secretary | - | 29/03/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
Bo Chen
CHM | Chairman | 52 | 23/04/2018 |
Changyu Wang
BRD | Director/Board Member | 61 | 03/03/2021 |
Gang Xu
BRD | Director/Board Member | 52 | 21/06/2018 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 6/13/25 A | Moonshot Holdings Ltd.
| Other | Company | 21,600,000 | 7.7216% | |
| 6/11/25 A | Moonshot Holdings Ltd.
| Other | Company | 18,800,000 | 6.7206% | |
| 9/15/23 A | Moonshot Holdings Ltd.
| Other | Company | 114,500 | 0.0409% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 2.26B 2.64B 336M 288M 269M 247M 465M 32.14B 472M 3.18B 1.24B 16.12B 1.26B 1.23B 53.29B | 2.13B 2.48B 316M 271M 253M 232M 436M 30.18B 444M 2.98B 1.17B 15.14B 1.19B 1.16B 50.05B |
| Net income | 600M 699M 89.19M 76.51M 71.44M 65.55M 123M 8.53B 125M 843M 330M 4.28B 335M 328M 14.14B | -18.88M -21.99M -2.8M -2.41M -2.25M -2.06M -3.88M -268M -3.94M -26.5M -10.38M -134M -10.53M -10.3M -444M |
| Net Debt | -1.25B -1.45B -185M -159M -148M -136M -256M -17.69B -260M -1.75B -685M -8.87B -695M -680M -29.34B | -1.39B -1.62B -206M -177M -165M -152M -285M -19.72B -290M -1.95B -764M -9.89B -775M -758M -32.7B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 20/08/26 | HK$81.30 | +5.52% | 1,442,500 |
| 19/08/26 | HK$77.05 | -1.28% | 1,224,849 |
| 18/08/26 | HK$78.05 | +0.90% | 1,085,326 |
| 17/08/26 | HK$77.35 | -1.02% | 1,487,466 |
| 14/08/26 | HK$78.15 | -1.26% | 1,168,500 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 2162 Stock
Select your edition
All financial news and data tailored to specific country editions
